| Literature DB >> 31730474 |
Morgan M Millar1,2, Joanne W Elena3, Lisa Gallicchio3, Sandra L Edwards4, Marjorie E Carter4, Kimberly A Herget4, Carol Sweeney5,4,6.
Abstract
BACKGROUND: Central cancer registries are often used to survey population-based samples of cancer survivors. These surveys are typically administered via paper or telephone. In most populations, web surveys obtain much lower response rates than paper surveys. This study assessed the feasibility of web surveys for collecting patient-reported outcomes via a central cancer registry.Entities:
Keywords: Cancer registry; Cancer survivors; Patient-reported outcomes; Response rate; Survey mode; Surveys; Web surveys; Web-push design
Year: 2019 PMID: 31730474 PMCID: PMC6858678 DOI: 10.1186/s12874-019-0859-9
Source DB: PubMed Journal: BMC Med Res Methodol ISSN: 1471-2288 Impact factor: 4.615
Fig. 1Experimental randomization and response outcomes for a survey of Utah cancer survivors1. 1 Because the pre-notification letter did not yet elicit responses, it is not included in the figure
Characteristics of the eligible sample for a survey of Utah cancer survivors
| Full sample | Paper | Web | |||||
|---|---|---|---|---|---|---|---|
| N | Col. % | N | Col. % | N | Col. % | ||
| All cases | 446 | 100.0 | 226 | 100.0 | 220 | 100.0 | |
| Time since diagnosis1 | 0.805 | ||||||
| Long-term | 192 | 43.0 | 96 | 42.5 | 96 | 43.6 | |
| Short-term | 254 | 57.0 | 130 | 57.5 | 124 | 56.4 | |
| Sex | 0.803 | ||||||
| Female | 252 | 56.5 | 129 | 57.1 | 123 | 55.9 | |
| Male | 194 | 43.5 | 97 | 42.9 | 97 | 44.1 | |
| Current age | 0.600 | ||||||
| < 40 | 74 | 16.6 | 35 | 15.5 | 39 | 17.7 | |
| 40–49 | 126 | 28.3 | 68 | 30.1 | 58 | 26.4 | |
| 50–59 | 171 | 38.3 | 82 | 36.3 | 89 | 40.5 | |
| > =60 | 75 | 16.8 | 41 | 18.1 | 34 | 15.5 | |
| Diagnosis age | 0.882 | ||||||
| < 40 | 102 | 22.9 | 53 | 23.5 | 49 | 22.3 | |
| 40–49 | 212 | 47.5 | 104 | 46.0 | 108 | 49.1 | |
| 50–59 | 98 | 22.0 | 50 | 22.1 | 48 | 21.8 | |
| > =60 | 34 | 7.6 | 19 | 8.4 | 15 | 6.8 | |
| Race2 | 0.650 | ||||||
| White | 416 | 93.3 | 212 | 93.8 | 204 | 92.7 | |
| Nonwhite | 30 | 6.7 | 14 | 6.2 | 16 | 7.3 | |
| Ethnicity3 | 0.903 | ||||||
| Hispanic | 68 | 15.5 | 34 | 15.3 | 34 | 15.8 | |
| Non-Hispanic | 372 | 84.5 | 189 | 84.8 | 183 | 84.3 | |
| Geography | 0.093 | ||||||
| Rural | 61 | 13.7 | 37 | 16.4 | 24 | 10.9 | |
| Metropolitan | 385 | 86.3 | 189 | 83.6 | 196 | 89.1 | |
| Cancer site | 0.992 | ||||||
| Colorectal | 128 | 28.7 | 63 | 27.9 | 65 | 29.6 | |
| Myeloma | 64 | 14.4 | 32 | 14.2 | 32 | 14.6 | |
| Breast | 97 | 21.8 | 51 | 22.6 | 46 | 20.9 | |
| Ovarian | 63 | 14.1 | 32 | 14.2 | 31 | 14.1 | |
| Prostate | 94 | 21.1 | 48 | 21.2 | 46 | 20.9 | |
| Stage at diagnosis | 0.707 | ||||||
| In situ | 24 | 5.4 | 10 | 4.4 | 14 | 6.4 | |
| Localized | 211 | 47.3 | 111 | 49.1 | 100 | 45.5 | |
| Regional | 114 | 25.6 | 55 | 24.3 | 59 | 26.8 | |
| Distant4 | 97 | 21.8 | 50 | 22.1 | 47 | 21.4 | |
1. “Long-term” survivors were defined as > 5 years from diagnosis for breast, colorectal, and prostate and > 3 years for myeloma and ovarian cancer. “Short-term” survivors were those < 1 year from diagnosis as of sample selection (September 2016)
2. Due to small counts, all races other than white have been grouped for analysis
3. Ethnicity could not be established for 6 individuals. Percentages based on total number of survivors with ethnicity data
4. Because fewer than 5 sample members were unstaged, they have been grouped together with distant stage to maintain confidentiality
Response outcomes by survey mode and brochure enclosure, survey of Utah cancer survivors
| Sample | Responded1 | Adjusted Risk Ratio2 | 95% CI | ||
|---|---|---|---|---|---|
| % | |||||
| Overall | 446 | 209 | 46.9 | ||
| Survey mode | |||||
| Paper | 226 | 114 | 50.4 | 1.00 | Ref. |
| Web | 220 | 95 | 43.2 | 0.88 | 0.72, 1.07 |
| Brochure | |||||
| No | 225 | 103 | 45.8 | 1.00 | Ref. |
| Yes | 221 | 106 | 48.0 | 1.03 | 0.85, 1.25 |
| Brochure by mode3 | |||||
| Paper, no brochure | 115 | 58 | 50.4 | 1.00 | Ref. |
| Paper, brochure | 111 | 56 | 50.5 | 0.97 | 0.75, 1.25 |
| Web, no brochure | 110 | 45 | 40.9 | 1.00 | Ref. |
| Web, brochure | 110 | 50 | 45.5 | 1.08 | 0.81, 1.45 |
1. The percentage of cases that responded equates to response rate (AAPOR RR1)
2. Risk ratios from multivariable models predicting survey response that include design features and adjust for time since diagnosis, sex, age, race, ethnicity, geography, cancer site, and cancer stage at diagnosis. In these models, none of the demographic or cancer variables significantly predicted response
3. When conducting the model using a single reference group to compare all four mode-brochure combinations simultaneously, the adjusted risk ratios were as follows: Paper, no brochure: Ref.; Paper, brochure: RR = 0.98 (95% CI: 0.76, 1.27); Web, no brochure: RR = 0.83 (95% CI: 0.62, 1.10); Web, brochure: RR = 0.91 (95% CI: 0.70, 1.18)
Comparison of respondents to non-respondents in a survey of Utah cancer survivors1,2
| Full sample | Paper | Web | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-respondents | Respondents | Non-respondents | Respondents | Non-respondents | Respondents | ||||||||||
| n | % | n | % | n | % | n | % | n | % | n | % | ||||
| Time since diagnosis | 0.144 | 0.076 | |||||||||||||
| Long-term | 114 | 59.4 | 78 | 40.6 | 53 | 55.2 | 43 | 44.8 | 61 | 63.5 | 35 | 36.5 | |||
| Recent | 123 | 48.4 | 131 | 51.6 | 59 | 45.4 | 71 | 54.6 | 64 | 51.6 | 60 | 48.4 | |||
| Sex | 0.130 | 0.760 | |||||||||||||
| Female | 126 | 50.0 | 126 | 50.0 | 55 | 42.6 | 74 | 57.4 | 71 | 57.7 | 52 | 42.3 | |||
| Male | 111 | 57.2 | 83 | 42.8 | 57 | 58.8 | 40 | 41.2 | 54 | 55.7 | 43 | 44.3 | |||
| Current age | 0.223 | 0.139 | |||||||||||||
| < 40 | 47 | 63.5 | 27 | 36.5 | 21 | 60.0 | 14 | 40.0 | 26 | 66.7 | 13 | 33.3 | |||
| 40–49 | 62 | 49.2 | 64 | 50.8 | 34 | 50.0 | 34 | 50.0 | 28 | 48.3 | 30 | 51.7 | |||
| 50–59 | 97 | 56.7 | 74 | 43.3 | 42 | 51.2 | 40 | 48.8 | 55 | 61.8 | 34 | 38.2 | |||
| > =60 | 31 | 41.3 | 44 | 58.7 | 15 | 36.6 | 26 | 63.4 | 16 | 47.1 | 18 | 52.9 | |||
| Race | 0.055 | 0.558 | |||||||||||||
| White | 216 | 51.9 | 200 | 48.1 | 104 | 49.1 | 108 | 50.9 | 112 | 54.9 | 92 | 45.1 | |||
| Nonwhite | 21 | 70.0 | 9 | 30.0 | 8 | 57.1 | 6 | 42.9 | 13 | 81.3 | < 53 | – | |||
| Ethnicity | 0.439 | ||||||||||||||
| Hispanic | 45 | 66.2 | 23 | 33.8 | 19 | 55.9 | 15 | 44.1 | 26 | 76.5 | 8 | 23.5 | |||
| Non-Hispanic | 189 | 50.8 | 183 | 49.2 | 92 | 48.7 | 97 | 51.3 | 97 | 53.0 | 86 | 47.0 | |||
| Geography | 0.909 | 0.904 | 0.874 | ||||||||||||
| Rural | 32 | 52.5 | 29 | 47.5 | 18 | 48.7 | 19 | 51.4 | 14 | 58.3 | 10 | 41.7 | |||
| Metro-politan | 205 | 53.3 | 180 | 46.8 | 94 | 49.7 | 95 | 50.3 | 111 | 56.6 | 85 | 43.4 | |||
| Cancer site | 0.144 | 0.074 | 0.728 | ||||||||||||
| Colorectal | 77 | 60.2 | 51 | 39.8 | 37 | 58.7 | 26 | 41.3 | 40 | 61.5 | 25 | 38.5 | |||
| Myeloma | 31 | 48.4 | 33 | 51.6 | 12 | 37.5 | 20 | 62.5 | 19 | 59.4 | 13 | 40.6 | |||
| Breast | 51 | 52.6 | 46 | 47.4 | 24 | 47.1 | 27 | 52.9 | 27 | 58.7 | 19 | 41.3 | |||
| Ovarian | 26 | 41.3 | 37 | 58.7 | 11 | 34.4 | 21 | 65.6 | 15 | 48.4 | 16 | 51.6 | |||
| Prostate | 52 | 55.3 | 42 | 44.7 | 28 | 58.3 | 20 | 41.7 | 24 | 52.2 | 22 | 47.8 | |||
| Stage | 0.174 | 0.162 | 0.652 | ||||||||||||
| In situ | 10 | 41.7 | 14 | 58.3 | < 53 | – | 7 | 70.0 | 7 | 50.0 | 7 | 50.0 | |||
| Localized | 118 | 55.9 | 93 | 44.1 | 57 | 51.4 | 54 | 48.7 | 61 | 61.0 | 39 | 39.0 | |||
| Regional | 65 | 57.0 | 49 | 43.0 | 32 | 58.2 | 23 | 41.8 | 33 | 55.9 | 26 | 44.1 | |||
| Distant | 44 | 45.4 | 53 | 54.6 | 20 | 40.0 | 30 | 60.0 | 24 | 51.1 | 23 | 48.9 | |||
1. Percent of respondents equates to response rate
2. P-values for statistically significant comparisons are presented in boldface.
3. Cell counts less than five are masked for protection of confidentiality
Demographic representativeness of respondents by survey mode, survey of Utah cancer survivors1
| Full sample | Paper | Web | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Respondents | Adj. RR2 | 95% CI | Respondents | Adj. RR2 | 95% CI | |||||||
| n | Col.% | n | Col.% | n | Col.% | |||||||
| Time since diagnosis | ||||||||||||
| Long-term | 192 | 43.0 | 43 | 37.7 | 1.00 | Ref. | 35 | 36.8 | 1.00 | Ref. | ||
| Short-term | 254 | 57.0 | 71 | 62.3 | 1.36 | 1.01, 1.84 | 60 | 63.2 | 1.07 | 0.74, 1.54 | 0.719 | |
| Sex | ||||||||||||
| Female | 252 | 56.5 | 74 | 64.9 | 1.39 | 0.91, 2.12 | 0.127 | 52 | 54.7 | 0.75 | 0.46, 1.22 | 0.249 |
| Male | 194 | 43.5 | 40 | 35.1 | 1.00 | Ref. | 43 | 45.3 | 1.00 | Ref. | ||
| Current age | ||||||||||||
| < 40 | 74 | 16.6 | 14 | 12.3 | 1.00 | Ref. | 13 | 13.7 | 1.00 | Ref. | ||
| 40–49 | 126 | 28.3 | 34 | 29.8 | 1.34 | 0.83, 2.16 | 0.238 | 30 | 31.6 | 1.49 | 0.86, 2.59 | 0.157 |
| 50–59 | 171 | 38.3 | 40 | 35.1 | 1.67 | 0.99, 2.80 | 0.053 | 34 | 35.8 | 1.06 | 0.59, 1.89 | 0.856 |
| > =60 | 75 | 16.8 | 26 | 22.8 | 1.78 | 1.02, 3.06 | 18 | 19.0 | 1.56 | 0.80, 3.06 | 0.196 | |
| Race | ||||||||||||
| White | 416 | 93.3 | 108 | 94.7 | 1.00 | Ref. | 92 | 96.8 | 1.00 | Ref. | ||
| Nonwhite | 30 | 6.7 | 6 | 5.3 | 0.76 | 0.41, 1.41 | 0.379 | < 53 | – | 0.45 | 0.16, 1.29 | 0.138 |
| Ethnicity | ||||||||||||
| Hispanic | 68 | 15.5 | 15 | 13.4 | 0.90 | 0.60, 1.35 | 0.611 | 8 | 8.5 | 0.51 | 0.27, 0.96 | |
| Non-Hispanic | 372 | 84.6 | 97 | 86.6 | 1.00 | Ref. | 86 | 91.5 | 1.00 | Ref. | ||
| Geography | ||||||||||||
| Rural | 61 | 13.7 | 19 | 16.7 | 0.84 | 0.57, 1.21 | 0.347 | 10 | 10.5 | 0.91 | 0.55, 1.51 | 0.728 |
| Metropolitan | 385 | 86.3 | 95 | 83.3 | 1.00 | Ref. | 85 | 89.5 | 1.00 | Ref. | ||
| Cancer site | ||||||||||||
| Colorectal | 128 | 28.7 | 26 | 22.8 | 1.00 | Ref. | 25 | 26.3 | 1.00 | Ref. | ||
| Myeloma | 64 | 14.4 | 20 | 17.5 | 1.45 | 0.77, 2.73 | 0.256 | 13 | 13.7 | 0.78 | 0.40, 1.54 | 0.480 |
| Breast | 97 | 21.8 | 27 | 23.7 | 0.92 | 0.57, 1.50 | 0.745 | 19 | 20.0 | 1.18 | 0.63, 2.21 | 0.597 |
| Ovarian | 63 | 14.1 | 21 | 18.4 | 1.26 | 0.79, 2.03 | 0.334 | 16 | 16.8 | 1.51 | 0.85, 2.68 | 0.157 |
| Prostate | 94 | 21.1 | 20 | 17.5 | 0.89 | 0.51, 1.56 | 0.687 | 22 | 23.2 | 1.22 | 0.72, 2.04 | 0.459 |
| Stage | ||||||||||||
| In situ | 24 | 5.4 | 7 | 6.1 | 1.00 | Ref. | 7 | 7.4 | 1.00 | Ref. | ||
| Localized | 211 | 47.3 | 54 | 47.4 | 0.76 | 0.44, 1.30 | 0.313 | 39 | 41.1 | 0.74 | 0.37, 1.46 | 0.383 |
| Regional | 114 | 25.6 | 23 | 20.2 | 0.60 | 0.34, 1.07 | 0.086 | 26 | 27.4 | 0.86 | 0.43, 1.71 | 0.667 |
| Distant | 97 | 21.8 | 30 | 26.3 | 0.59 | 0.28, 1.21 | 0.149 | 23 | 24.2 | 1.11 | 0.52, 2.39 | 0.786 |
1. P-values for statistically significant comparisons are presented in boldface
2. Adjusted (Adj.) risk ratios from a multivariable model that adjusts for other variables in table
3. Cell counts less than five are masked for protection of confidentiality